Analysis of the drug prescription for obese patients in Moscow

Objectives. Obesity is a chronic relapsing disease that requires long-term and lifelong treatment. The development of diseases associated with obesity may cause the additional need for prescribing drug therapy. The main aim was to analyze the structure of preferential drug prescriptions for patients...

Full description

Bibliographic Details
Main Authors: V. S. Krysanova, M. V. Zhuravleva, I. S. Krysanov, V. Yu. Ermakova
Format: Article
Language:Russian
Published: Izdatelstvo OKI 2020-05-01
Series:Качественная клиническая практика
Subjects:
Online Access:https://www.clinvest.ru/jour/article/view/489
id doaj-32b3f51fd6f846eabb3f308c011bd39e
record_format Article
spelling doaj-32b3f51fd6f846eabb3f308c011bd39e2020-11-25T02:37:15ZrusIzdatelstvo OKIКачественная клиническая практика2588-05192618-84732020-05-0101536010.37489/2588-0519-2020-1-53-60473Analysis of the drug prescription for obese patients in MoscowV. S. Krysanova0M. V. Zhuravleva1I. S. Krysanov2V. Yu. Ermakova3FSAEI HE I.M. Sechenov First MSMU MOH Russia, Russia, Moscow; State Budgetary Institution of the Moscow region “Clinical and Economic Analysis Scientific-Practical Center of the Moscow Region Healthcare Ministry”, Russia, Krasnogorsk; Medical Institute of Continuing Education, MSUFP, Russia, MoscowFSAEI HE I.M. Sechenov First MSMU MOH Russia, Russia, MoscowMedical Institute of Continuing Education, MSUFP, Russia, Moscow; Institute of Clinical and Economic Assessment and Pharmacoeconomics, JSC, Russia, MoscowFSAEI HE I.M. Sechenov First MSMU MOH Russia, Russia, Moscow; Medical Institute of Continuing Education, MSUFP, Russia, Moscow; Institute of Clinical and Economic Assessment and Pharmacoeconomics, JSC, Russia, MoscowObjectives. Obesity is a chronic relapsing disease that requires long-term and lifelong treatment. The development of diseases associated with obesity may cause the additional need for prescribing drug therapy. The main aim was to analyze the structure of preferential drug prescriptions for patients with obesity for the period 2015-2018 in Moscow. Methods. A pharmacoepidemiological retrospective analysis of the structure of drug prescriptions for the period 2015-2018 in Moscow according to the chosen nosology — obesity (code ICD-10 — E66) was performed. The total number of patients receiving medications, the total number of prescribed prescriptions and packages were analyzed. The results are processed using the MS Excel 2013 package and are presented in the form of absolute values, shares (%). Results. For the period from 2015-2018 there is a 3.5-fold increase in the number of obese patients receiving preferential drugs — from 259 people up to 899 people. Over the entire analyzed period, there is a gradual increase in the proportion of drugs for the treatment of diabetes (from 43.1 to 51.6 %), mainly due to metformin, and for the treatment of the gastrointestinal tract (from 6.7 to 18.7 %). The total costs of drug therapy for obese patients over the analyzed period increased by 3.6 times. The largest share of the costs was attributed to drugs for the treatment of diabetes mellitus (from 38.1 to 62.5 %). Conclusions. Analysis can help to improve the system of rational distribution of financial resources for the drug provision of obese patients through the development of clinical and economic approaches that allow choosing the most effective and less costly approaches to providing medical care to patients.https://www.clinvest.ru/jour/article/view/489obesitydrug prescriptioncostspharmacoepidemiology
collection DOAJ
language Russian
format Article
sources DOAJ
author V. S. Krysanova
M. V. Zhuravleva
I. S. Krysanov
V. Yu. Ermakova
spellingShingle V. S. Krysanova
M. V. Zhuravleva
I. S. Krysanov
V. Yu. Ermakova
Analysis of the drug prescription for obese patients in Moscow
Качественная клиническая практика
obesity
drug prescription
costs
pharmacoepidemiology
author_facet V. S. Krysanova
M. V. Zhuravleva
I. S. Krysanov
V. Yu. Ermakova
author_sort V. S. Krysanova
title Analysis of the drug prescription for obese patients in Moscow
title_short Analysis of the drug prescription for obese patients in Moscow
title_full Analysis of the drug prescription for obese patients in Moscow
title_fullStr Analysis of the drug prescription for obese patients in Moscow
title_full_unstemmed Analysis of the drug prescription for obese patients in Moscow
title_sort analysis of the drug prescription for obese patients in moscow
publisher Izdatelstvo OKI
series Качественная клиническая практика
issn 2588-0519
2618-8473
publishDate 2020-05-01
description Objectives. Obesity is a chronic relapsing disease that requires long-term and lifelong treatment. The development of diseases associated with obesity may cause the additional need for prescribing drug therapy. The main aim was to analyze the structure of preferential drug prescriptions for patients with obesity for the period 2015-2018 in Moscow. Methods. A pharmacoepidemiological retrospective analysis of the structure of drug prescriptions for the period 2015-2018 in Moscow according to the chosen nosology — obesity (code ICD-10 — E66) was performed. The total number of patients receiving medications, the total number of prescribed prescriptions and packages were analyzed. The results are processed using the MS Excel 2013 package and are presented in the form of absolute values, shares (%). Results. For the period from 2015-2018 there is a 3.5-fold increase in the number of obese patients receiving preferential drugs — from 259 people up to 899 people. Over the entire analyzed period, there is a gradual increase in the proportion of drugs for the treatment of diabetes (from 43.1 to 51.6 %), mainly due to metformin, and for the treatment of the gastrointestinal tract (from 6.7 to 18.7 %). The total costs of drug therapy for obese patients over the analyzed period increased by 3.6 times. The largest share of the costs was attributed to drugs for the treatment of diabetes mellitus (from 38.1 to 62.5 %). Conclusions. Analysis can help to improve the system of rational distribution of financial resources for the drug provision of obese patients through the development of clinical and economic approaches that allow choosing the most effective and less costly approaches to providing medical care to patients.
topic obesity
drug prescription
costs
pharmacoepidemiology
url https://www.clinvest.ru/jour/article/view/489
work_keys_str_mv AT vskrysanova analysisofthedrugprescriptionforobesepatientsinmoscow
AT mvzhuravleva analysisofthedrugprescriptionforobesepatientsinmoscow
AT iskrysanov analysisofthedrugprescriptionforobesepatientsinmoscow
AT vyuermakova analysisofthedrugprescriptionforobesepatientsinmoscow
_version_ 1724795780282187776